Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 73, Issue 2, 2006, Pages 150-157

  Kitagawa, Nagako ^a   Yano, Yutaka ^a   Gabazza, Esteban C ^a   Bruno, Nelson E ^a   Araki, Rika ^a   Matsumoto, Kazutaka ^a   Katsuki, Akira ^a   Hori, Yasuko ^a   Nakatani, Kaname ^a   Taguchi, Osamu ^a   Sumida, Yasuhiro ^a   Suzuki, Koji ^a   Adachi, Yukihiko ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibrinolysis; Insulin resistance; Type 2 diabetes mellitus; Visceral fat

Indexed keywords

HEMOGLOBIN A1C; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SUBCUTANEOUS FAT; UNIVARIATE ANALYSIS;

BODY MASS INDEX; CARBOXYPEPTIDASE U; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 33745234038     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.12.008     Document Type: Article

References (42)

1. Kannel W.B., D'Agostino R.B., Wilson P.W.F., Belanger A.J., and Gagnon D.R. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am. Heart J. 120 (1990) 672-676
2. Hamsten A. Hemostatic function and coronary artery disease. N. Engl. J. Med. 332 (1995) 677-678
3. Gabazza E.C., Takeya H., Deguchi H., Sumida Y., Taguchi O., Murata T., et al. Protein C activation in NIDDM patients. Diabetologia 39 (1996) 1455-1461
4. Yano Y., Kitagawa N., Gabazza E.C., Morioka K., Urakawa H., Tanaka T., et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 88 (2003) 736-741
5. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 270 (1995) 14477-14484
6. Wang W., Boffa M.B., Bajzar L., Walker J.B., and Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 273 (1998) 27176-27181
7. Aubert H., Frere C., Aillaud M.F., Morange P.E., Juhan-Vague I., and Alessi M. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J. Thromb. Haemost. 1 (2003) 791-797
8. Schroeder V., Chatterjee T., Mehta H., Windecker S., Pham T., Devantay N., et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb. Haemost. 88 (2002) 1020-1025
9. Hori Y., Gabazza E.C., Yano Y., Katsuki A., Suzuki K., Adachi Y., et al. Insulin resistance is associated with increased circulating levels of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87 (2002) 660-665
10. Kruszynska Y.T., Yu J.G., Olefsky J.M., and Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49 (2000) 633-639
11. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 8549 (1987) 3-9
12. Juhan-Vague I., and Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78 (1997) 656-660
13. Aso Y., Matsumoto S., Fujiwara Y., Tayama K., Inukai T., and Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 51 (2002) 471-476
14. Boffa M.B., Hamill J.D., Maret D., Brown D., Scott M.L., Nesheim M.E., et al. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J. Biol. Chem. 278 (2003) 9250-9257
15. Gabriely I., Yang X.M., Cases J.A., Ma X.H., Rossetti L., and Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 160 (2002) 115-122
16. Katsuki A., Sumida Y., Urakawa H., Gabazza E.C., Murashima S., Maruyama N., et al. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 26 (2003) 2341-2344
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20 (1997) 1183-1197.
18. Mogensen C.E., and Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 311 (1984) 89-93
19. Fujimoto H., Gabazza E.C., Hataji O., Yuda H., D'Alessandro-Gabazza C.N., Nakano M., et al. Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease. Am. J. Respir. Crit. Care Med. 167 (2003) 1687-1694
20. Tomas E., Lin Y.S., Dagher Z., Saha A., Luo Z., Ido Y., et al. Hyperglycemia and insulin resistance: possible mechanisms. Ann. N. Y. Acad. Sci. 967 (2002) 43-51
21. Katsuki A., Sumida Y., Murashima S., Murata K., Takarada Y., Ito K., et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 88 (1998) 859-862
22. Boffa M.B., Hamill J.D., Bastajian N., Dillon R., Nesheim M.E., and Koschinsky M.L. A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 277 (2002) 25329-25336
23. Way K.J., Katai N., and King G.L. Protein kinase C and the development of diabetic vascular complications. Diabet. Med. 18 (2001) 945-959
24. Kumar A., Hawkins K.S., Hannan M.A., and Ganz M.B. Activation of PKC-beta(I) in glomerular mesangial cells is associated with specific NF-kappaB subunit translocation. Am. J. Physiol. Renal Physiol. 281 (2001) F613-F620
25. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50 (2001) 2792-2808
26. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 2 (1996) 800-803
27. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., and Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46 (1997) 860-867
28. Kockx M., Leenen R., Seidell J., Princen H.M., and Kooistra T. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb. Haemost. 82 (1999) 1490-1496
29. Raji A., Seely E.W., Arky R.A., and Simonson D.C. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J. Clin. Endocrinol. Metab. 86 (2001) 5366-5371
30. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab. Res. Rev. 16 (2000) 192-201
31. Goldberg H.J., Whiteside C.I., and Fantus I.G. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. J. Biol. Chem. 277 (2002) 33833-33841
32. McGill J.B., Schneider D.J., Arfken C.L., Lucore C.L., and Sobel B.E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43 (1994) 104-109
33. Lyon C.J., and Hsueh W.A. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am. J. Med. 115 (2003) 62S-68S
34. De Taeye B., Smith L.H., and Vaughan D.E. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr. Opin. Pharmacol. 5 (2005) 149-154
35. Vague P., Juhan-Vague I., Aillaud M.F., Badier C., Viard R., Alessi M.C., et al. Correlation between fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35 (1986) 250-253
36. Anfosso F., Chomiki N., Alessi M.C., Vague P., and Juhan-Vague I. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2 Metformin inhibits the stimulating effect of insulin. J. Clin. Invest. 91 (1993) 2185-2193
37. Schneider D.J., Absher P.M., and Ricci M.A. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation 96 (1997) 2868-2876
38. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 546-551
39. Calles-Escandon J., Mirza S.A., Sobel B.E., and Schneider D.J. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 47 (1998) 290-293
40. Taniwaki H., Kawagishi T., Emoto M., Shoji T., Kanda H., Maekawa K., et al. Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes. Diabetes Care 22 (1999) 1851-1857
41. Cruickshank K., Riste L., Anderson S.G., Wright J.S., Dunn G., and Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 106 (2002) 2085-2090
42. Kondo K., Kitagawa K., Nagai Y., Yamagami H., Hashimoto H., Hougaku H., et al. Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression. Atherosclerosis 179 (2005) 155-160